Match!
Kojiro Shimozuma
Ritsumeikan University
127Publications
23H-index
1,437Citations
Publications 127
Newest
#2Takashi FukudaH-Index: 16
Last.Kojiro Shimozuma (Rits: Ritsumeikan University)H-Index: 23
view all 3 authors...
Purpose This study aimed to assess psychometric properties of the Japanese version of the EQ-5D-Y (3 levels) with a focus on feasibility, reliability, and construct validity.
Source
#1Hideki Murasawa (Rits: Ritsumeikan University)H-Index: 2
#2Takayuki Sugiyama (Hamamatsu University)H-Index: 7
Last.Kojiro Shimozuma (Rits: Ritsumeikan University)H-Index: 23
view all 14 authors...
Purpose The goal of the present study was to determine factors related to a ceiling effect (CE) on the EQ-5D-5L among Japanese patients with prostate cancer (PC).
Source
#1Hideki Murasawa (Rits: Ritsumeikan University)H-Index: 2
#2Takayuki Sugiyama (Hamamatsu University)H-Index: 7
Last.Kojiro Shimozuma (Rits: Ritsumeikan University)H-Index: 23
view all 12 authors...
Purpose To obtain health utility data to allow for cost-effectiveness analysis in groups stratified by disease progression along with health-related quality of life (HRQoL) information in Japanese prostate cancer (PC) patients.
2 CitationsSource
#1Masato TakahashiH-Index: 21
#2Masataka SawakiH-Index: 15
Last.Naruto TairaH-Index: 19
view all 12 authors...
OBJECTIVE: The effect of trastuzumab(Tmab) or chemotherapy on cognitive function has not been fully understood, especially in elderly breast cancer patients. The RESPECT trial compared 1-year(yr) Tmab monotherapy with Tmab plus standard chemotherapy as adjuvant therapy in elderly patients with HER2-positive breast cancer. The primary objective was to verify the noninferiority of 1-yr Tmab monotherapy compared to Tmab plus chemotherapy in terms of disease-free survival, and the planned analysis s...
Source
#1Kokoro KobayashiH-Index: 6
#2Naruto TairaH-Index: 19
Last.Hirofumi MukaiH-Index: 21
view all 12 authors...
OBJECTIVE: The RESPECT trial compared 1-year trastuzumab monotherapy with trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients. Primary objective of this study was to verify the noninferiority of 1-year trastuzumab monotherapy to trastuzumab plus chemotherapy in terms of disease free survival, and the planned analysis showed that the difference of restricted mean survival time between two groups at 3 years was 0.45 months (rep...
Source
#1Takanori WatanabeH-Index: 5
#2Hiroshi Yagata (Saitama Medical University)H-Index: 3
Last.Yasuo Ohashi (Chu-Dai: Chuo University)H-Index: 19
view all 16 authors...
Purpose Many breast cancer patients suffer from chemotherapy-induced hair loss. Accurate information about temporal changes in chemotherapy-induced hair loss is important for supporting patients scheduled to receive chemotherapy, because it helps them to prepare. However, accurate information, on issues such as the frequency of hair loss after chemotherapy, when regrowth starts, the condition of regrown hair, and the frequency of incomplete hair regrowth, is lacking. This study aimed to clarify ...
Source
#2Hideki MurasawaH-Index: 2
Last.Kojiro ShimozumaH-Index: 23
view all 5 authors...
Source
Source
#1Hideki MurasawaH-Index: 2
#2Takashi OkabeH-Index: 2
Last.Kojiro ShimozumaH-Index: 23
view all 8 authors...
Source
#1S. NotoH-Index: 5
#2Takashi FukudaH-Index: 16
Last.M KobayashiH-Index: 2
view all 10 authors...
Source
12345678910